# RO7771950

Source: https://onco.cc/drugs/ro7771950/  
OnCo record `ro7771950` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

RO7771950 is an experimental small-molecule drug from Hoffmann-La Roche in phase 3 trials for HER2-positive breast cancer and HR-positive / HER2-negative breast cancer, aimed at HER2.

## Summary

RO7771950 (A-1041, RG6596) is a small-molecule drug developed by Hoffmann-La Roche. Its target is HER2 (the sponsor names HER2). The sponsor states: A blood-brain-barrier-penetrant HER2-targeted inhibitor, studied orally in combination with trastuzumab and capecitabine in HER2-positive breast cancer, including patients with CNS metastases. ClinicalTrials.gov describes the intervention as: Participants will receive one of two doses of RO7771950 orally (PO) twice a day (BID). It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT07413939 (RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive), in HER2-positive breast cancer and HR-positive / HER2-negative breast cancer. The largest, NCT07413939, plans to enrol 650 participants with primary completion expected 2029-05-01. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-11
- Also known as: ZN-A-1041
- Tags: pipeline; ctgov-ingest
- Code: A-1041, RG6596
- Modality: small molecule
- Mechanism: A blood-brain-barrier-penetrant HER2-targeted inhibitor, studied orally in combination with trastuzumab and capecitabine in HER2-positive breast cancer, including patients with CNS metastases.

## Sources

- ClinicalTrials.gov: trials of RO7771950: https://clinicaltrials.gov/search?intr=A-1041

## Connected records

- cancers: [HER2-positive breast cancer](https://onco.cc/cancers/breast-her2-positive/), [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/)
- targets: [HER2](https://onco.cc/targets/her2/)
- companies: [Roche / Genentech](https://onco.cc/companies/roche-genentech/)
- trials: [A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced So](https://onco.cc/trials/nct05593094/), [RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive](https://onco.cc/trials/nct07413939/)

---
JSON: https://onco.cc/api/v1/entities/ro7771950.json